NCI Cancer Bulletin for June 29, 2010 Name of the Trial A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-resistant Prostate Cancer (NCI-09-C-0195). See the protocol summary . Dr. William Dahut
NCI Cancer Bulletin for June 29, 2010 Gefitinib Improves Progression-free Survival for Metastatic Lung Cancers with EGFR Mutations Patients newly diagnosed with metastatic non-small cell lung cancer (NSCLC) who received gefitinib (Iressa) had significantly higher response rates and longer progression-free survival compared with patients who received carboplatin plus paclitaxel (73.7 percent versus 30.7 percent and 10.8 months versus 5.4 months, respectively), according to results of a phase III trial conducted in Japan. The results were published in the June 24 New England Journal of Medicine . All patients enrolled in the study had epidermal growth factor receptor (EGFR) mutations that were sensitive to the tyrosine kinase inhibitor (TKI) gefitinib. The patients did not have the resistant EGFR mutation T790M, and they had not been previously treated with chemotherapy. The researchers, led by Dr.
New developments in pancreatic cancer @AACR - Pharma Strategy Blog Pancreatic cancer is a devastating disease with a generally poor prognosis, largely because it is usually detected in late stage disease where chemotherapy options generally have a limited effect. Typically response rates with gemcitabine are around 5%, with advanced patients living around 5-6 months on average. Erlotinib, an EGFR inhibitor, is also approved in the USA for treatment of the disease, but the therapy only adds approximately two weeks to survival.
I did a double take at my inbox alerts this morning as things have been rather quiet of late in the Pharma and Biotech world. You can read the financial aspects of the deal in Celgene's press release. While the timing might be a little bit of a surprise, the strategic acquisition is not and makes a lot of commercial sense for Celgene. Celgene buy Abraxis Bioscience for $2.9B - Pharma Strategy Blog
Childhood's Cures Haunted by Adulthood's 'Late Effects' -- Marder 328 (5985): 1474 -- Science
NCI Cancer Bulletin for June 29, 2010 Gefitinib Improves Progression-free Survival for Metastatic Lung Cancers with EGFR Mutations Patients newly diagnosed with metastatic non-small cell lung cancer (NSCLC) who received gefitinib (Iressa) had significantly higher response rates and longer progression-free survival compared with patients who received carboplatin plus paclitaxel (73.7 percent versus 30.7 percent and 10.8 months versus 5.4 months, respectively), according to results of a phase III trial conducted in Japan. The results were published in the June 24 New England Journal of Medicine .
Obesity increases the risk of cancer death among Asians too | Booster Shots | Los Angeles Times Historically, obesity has been a problem of western countries. For instance, nearly 1 in 3 Americans is obese (defined as having a body mass index that tops 30), as are about 1 in 4 members of the United Kingdom. According to this ranking compiled with data from the Organization for Economic Cooperation and Development, the most obese countries in Asia are Japan and South Korea, where a mere 3.2% of the population has a BMI over 30. But with obesity rates rising in China, South Korea, Thailand, Singapore and other Asian countries, an international group of researchers wondered how those extra pounds might be raising the risk of death from cancer.
Update: MELA Sciences priced 2.2 million shares of stock at $7.50 a share Wednesday. MELA expects to gross about $17.5 million, including the sale of over-allotment shares. MELA tried to get $8 a share for the stock offering Tuesday night, according to a source familiar with the deal terms. IRVINGTON, NY (TheStreet) -- MELA Sciences (MELA_) CEO Joseph Gulfo explained to investors on a Tuesday night conference call that the company decided to raise money now -- just two months shy of an all-important FDA advisory panel reviewing the company's melanoma skin cancer detection device -- because investors are worried that MELA is running short on cash. Hmm... MELA's Stock Sale Suggests Problems for Skin Cancer Detector
Celgene strikes $2.9B deal to acquire Abraxis With an eye to burnishing its oncology rep and its already sizable revenue, Celgene has struck a deal to buy Abraxis BioScience for cash and stock totaling $2.9 billion. The buyout gives Celgene control of Abraxane, now approved for breast cancer treatment, along with its discovery platform and a pipeline of experimental therapies. In exchange for every share of Abraxis, Celgene will pay $58 a share in cash and 0.2617 of a share of Celgene. That values Abraxis' shares at $71.93, a 17 percent bump on yesterday's close. Abraxis shareholders also stand to gain up to $650 million in additional milestone payments if Abraxane is approved for lung and pancreatic cancers. In addition to a slate of ongoing trials for Abraxane, Abraxis has one mid-stage trial underway, a Phase I and three preclinical programs listed on its website.
Ethnic Supplies Ltd's Photos - Ethnic Supplies At BBC GWL
Did you notice that lately, every time you search for a pharma brand on Google, the #1 organic result is always the NIH? Always? Always. It's not the brand.com site anymore. The Gov't Controls Google's Search Results for Your Brand. Surprised? | ePharma Rx
Celgene Acquires Abraxis for $2.9 Billion SUMMIT, N.J. (TheStreet) -- Celgene (CELG_) is acquiring Abraxis BioScience (ABII) for $2.9 billion in cash and stock to expand its cancer drug business, the company announced Wednesday. Celgene is one of the largest biotech companies in the world, with revenue of $2.7 billion last year coming mainly from drugs like Revlimid used to treat cancers of the blood. By acquiring Abraxis, Celgene gains ownership of a drug used to treat breast cancer patients and expands the company's commercial operations into the solid tumor market. "The acquisition of Abraxis BioScience is an exceptional strategic fit that will accelerate our strategy of becoming a global leader in oncology," said Bob Hugin, Celgene's CEO, in a statement.
I'm Had Enough: Half of BC Survivors Stop Tamoxifen Early This is a headline that quadruples my empathy factor: "Half of breast cancer patients stop taking hormone drugs." I've been there. I did that. And damn, I'm here to tell you about it. But first, here's what was reported, from USA Today by Liz Szabo Half of breast cancer patients stop taking hormone drugs and from the American Society of Clinical Oncology Fewer than half of breast cancer survivors adhere.... from a study of 8800 women with early-stage breast cancer. Researchers found that only 49 percent of the women completed the recommended regimen for tamoxifen, aromatase inhibitors or both.
Our worst habits are always the hardest ones to break, but if you can manage to insert at least a few of these positive habits into your daily routine, you’ll be ahead of the game. See a few below: Drink a glass of water when you wake up. 30 habits that will improve your life http://tinyurl.com/26e4wku
Quick Financial Fixes - Forbes.com
Here's an interesting and informative TED video I just came across, where Clay Shirky talks about cognitive surplus and how it will change the world. The idea behind the concept of "cognitive surplus" is that we use spare brain cycles while online to build a more cooperative world. In other words, new technologies enable loose collaborations to evolve. I'm not sure I like the term 'cognitive surplus' but Shirky is an eloquent, thoughtful and engaging speaker who is well worth listening to: How cognitive surplus will change the world: Clay Shirky - Pharma Strategy Blog
Community management isn’t what it used to be. Once upon a time, managing a community meant hanging out in an online location – be it a forum or a chat room – and moderating chat. Approving comments. Handling some support issues. Dealing with trolls, helping people with questions. That kind of thing. A Different Look at Community Management « Social Media Monitoring and Engagement – Radian6
Finding pharma on your mobile device (early opportunities for exploration) - HealthEd Blog Before looking at pharma companies testing out the mobile space, I want to introduce you to another healthcare organization that is diligently studying this channel. A hospital system, you say? Nope. Insurance plan? Sorry. It's actually none other than the US government.
Chain of transplants gives 14 kidney patients new life
Phil's Vacation: Day +5
Phil's Bone Marrow
800,000 Strong Boycott BP Facebook Fan Page Mysteriously Vanishes
Porter Novelli unveils global service for brands experiencing social media crises
Many Americans overtreated to death - Health - Cancer
UK scrambles to keep 'dozen eggs' in EU battle
Steve Woodruff - Yeah, this works...! - TwitVid
Gefitinib or Chemotherapy for Non–Small Cell Lung Cancer with Mutated EGFR - Pharma Strategy Blog
Regulation of PTEN/Akt and MAP kinase signaling pathways by the ubiquitin ligase activators Ndfip1 and Ndfip2 [Cell_Biology] http://tinyur..
Early dinner, something tasty to go with it and then several
Warfarin For Early Cancer Detection?
2010 FIFA World Cup: No doping positives for 4th straight World Cup
Chicago Journals - The Journal of Infectious Diseases
Podcamp Boston 5! - PCB5- Eventbrite
Share photos on Twitter
Eye on FDA: Clinical Trials and YouTube
Eye on FDA: Growing Use of Video Related to Clinical Trials
Inexpensive camera diagnoses cancer
Web-Based, Participant-Driven Studies Yield Novel Genetic Associations for Common Traits
@blehr11 neither but this was yummy on Twitpic
A Grand Hyatt Stay « StickyFigure